Previously, the US Secretary of Health and Human Services has asked the Food and Drug Administration (FDA) to reject Teva Pharmaceutical’s petition to make its Plan B and Plan B One Step pills available to young teens and girls without a prescription.
The verdict is expected to benefit not only Teva, but also Actavis and Perrigo, which produce generic versions of the drug.
Teva had recorded revenues of $88m in the US from Plan B One Step for the 12 months ending 31May 2012, according to IMS Health data.